HTG Molecular Diagnostics Inc. said QIAGEN Manchester Ltd. terminated its first statement of work related to the development and use of a next-generation sequencing-based clinical trial assay.

The termination of the statement, which relates to one of three development programs, is the subject of a sponsor project agreement between QIAGEN and an unnamed company.

The termination came after the unnamed company's project-related phase 3 drug trial failed to meet its endpoint.

Each of the three development programs is for a different pharmaceutical company under the commercialization and manufacturing agreement.

QIAGEN North American Holdings Inc. owns 833,333 shares of HTG Molecular and holds a subordinated convertible promissory note issued by the company in the principal amount of $3 million.

QIAGEN Manchester and QIAGEN North American are units of Qiagen NV.